Ventricular Arrythmia
Conditions
Keywords
Ventricular Arrhythmia, Prognosis
Brief summary
The investigation of biomarkers for immune status and metabolic state, as well as host microbiota composition, in patients with ventricular arrhythmias before and after radiofrequency ablation, can provide new insights for specific and personalized treatment. This can help establish early prediction and prognosis models and provide a basis for clinically effective diagnosis and treatment.
Detailed description
Abnormal immune and metabolic states can lead to the occurrence of various systemic diseases, including the development of cardiovascular diseases through multiple mechanisms. On the other hand, various diseases can also feedback and regulate the immune and metabolic systems. However, currently there is no research on the impact of immune and metabolic states on ventricular arrhythmia. Exploring the biomarker characteristics and risk stratification of patients with ventricular arrhythmias undergoing radiofrequency ablation before and after the procedure can provide new insights for specific and personalized treatment. It can establish early prediction and prognostic models, providing evidence for clinically effective diagnosis and treatment.
Interventions
Observational; No Interventions were given.
Sponsors
521 Hospital of NORINCO Group
Shaanxi Provincial People's Hospital
Xiangyang Central Hospital
Henan Provincial People's Hospital
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.
Exclusion criteria
* Age \<18 or \>80 years old; * Patients with autoimmune diseases or immune deficiencies, or those who have used immunosuppressive or immune modulating agents in the past 3 months; * Platelet count \<100×10\^9/L or functional platelet defects; * Congenital or acquired coagulation or bleeding disorders; * Patients with a history of organ transplantation or are preparing to receive organ transplantation; * Unwilling to sign an informed consent or cooperate with the examination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the incidence of MACCE | 3,6 months,1,3,5 years after enrollment. | Major adverse cardiovascular and cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the incidence of myocardial infarction | 3,6 months,1,3,5 years after enrollment. | Myocardial infarction diagnosed by clinical doctors will be assessed from the medical records. |
| Change in the incidence of stroke | 3,6 months,1,3,5 years after enrollment. | Stroke diagnosed by clinical doctors will be assessed from the medical records. |
| Change in the incidence of vessel revascularization | 3,6 months,1,3,5 years after enrollment. | Vessel revascularization assessed by clinical doctors will be assessed from the medical records. |
| Change in the incidence of all-cause death | 3,6 months,1,3,5 years after enrollment. | All-cause death diagnosed by clinical doctors will be assessed from the medical records. |
Countries
China
Contacts
Primary ContactGuoliang Li
Backup ContactChaofeng Sun
Outcome results
None listed